Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,269,975 | 2,089,719 | 1,791,665 | 1,705,552 | 1,954,372 |
| Marketable Securities | 2,461,955 | 2,640,026 | 1,932,557 | 1,345,191 | N/A |
| Receivables | 12,675,030 | 10,927,900 | 8,142,708 | 7,445,721 | 4,930,589 |
| Inventories | 5,923,105 | 4,618,957 | 3,453,341 | 3,121,701 | 2,839,715 |
| Other current assets | -5 | -2 | -1 | -5 | 357,264 |
| TOTAL | $23,330,060 | $20,276,600 | $15,320,270 | $13,618,160 | $10,081,940 |
| Non-Current Assets | |||||
| PPE Net | 23,560,760 | 13,207,540 | 9,440,613 | 8,808,094 | 7,701,211 |
| Investments And Advances | 388,165 | 241,468 | 190,169 | 229,263 | 252,474 |
| Intangibles | 16,108,050 | 8,770,951 | 7,280,505 | 6,868,506 | 3,164,652 |
| Other Non-Current Assets | 4,153,235 | 3,166,811 | 1,930,433 | 1,422,197 | 1,001,773 |
| TOTAL | $44,210,210 | $25,386,770 | $18,841,720 | $17,328,060 | $12,120,110 |
| Total Assets | $67,540,270 | $45,663,370 | $34,161,990 | $30,946,220 | $22,202,050 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,901,385 | 940,606 | 207,586 | 2,177,125 | 1,142,719 |
| Accounts payable and accrued liabilities | 4,182,670 | 3,717,991 | 2,207,119 | 1,411,217 | 875,844 |
| Other current liabilities | 24,048,690 | 18,942,070 | 13,706,310 | 11,662,670 | 8,147,789 |
| TOTAL | $31,541,560 | $24,633,910 | $17,125,100 | $15,833,000 | $10,765,820 |
| Non-Current Liabilities | |||||
| Long Term Debt | 13,002,730 | 2,980,666 | 3,443,429 | 2,062,095 | 443,820 |
| Other Non-Current Liabilities | 1,403,750 | 1,100,616 | 772,003 | 956,828 | 907,710 |
| TOTAL | $15,193,250 | $5,556,804 | $5,215,270 | $3,857,539 | $1,734,837 |
| Total Liabilities | $46,734,800 | $30,190,710 | $22,340,370 | $19,690,540 | $12,500,660 |
| Shareholders' Equity | |||||
| Common Shares | 64,670 | 65,485 | 64,570 | 73,504 | 72,004 |
| Retained earnings | 20,944,960 | 15,222,620 | 11,411,120 | 11,455,840 | 9,770,177 |
| Other shareholders' equity | -204,160 | 185,555 | 346,930 | -272,654 | -139,791 |
| TOTAL | $20,805,470 | $15,472,660 | $11,821,620 | $11,255,690 | $9,701,390 |
| Total Liabilities And Equity | $67,540,270 | $45,663,370 | $34,161,990 | $30,946,230 | $22,202,050 |